TNFSF13 and plasma cell myeloma: Our findings show that EV-derived proteins (PDIA3, BTN1A1, APRIL) and complement-associated proteins could be further explored in myeloma, as biomarkers across disease natural history and as potential new drug targets that could be monitored by PB sampling.